Trials / Completed
CompletedNCT03887520
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)
Multi-center Cross-sectional Epidemiological Study to Characterize the Prevalence and Distribution of Lipoprotein(a) Levels Among Patients With Established Cardiovascular Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 49,001 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Blood draw for Lp(a) | Collect sample for Lipoprotein(a) testing |
Timeline
- Start date
- 2018-11-27
- Primary completion
- 2021-07-30
- Completion
- 2021-07-30
- First posted
- 2019-03-25
- Last updated
- 2022-01-28
Locations
900 sites across 49 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, Egypt, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Lebanon, Malaysia, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom, Vietnam
Source: ClinicalTrials.gov record NCT03887520. Inclusion in this directory is not an endorsement.